Last month, the Centers for Medicare and Medicaid (CMS) released a draft memorandum regarding its national coverage determination of the class of monoclonal antibodies directed at beta-amyloid plaque ...

There has been considerable controversy surrounding Aduhelm since the Food and Drug Administration (FDA) granted the drug accelerated approval in 2021. The accelerated approval of Aduhelm has been ...

Biogen is trying to escape the dark Aduhelm cloud hanging over its Alzheimer's disease drug launch. So far, the launch has triggered layoffs, a CEO switch and much more. Now, Biogen has quietly ...

With federal payment for Biogen’s controversial Alzheimer’s disease drug, Aduhelm, restricted to clinical trials only, neurologists don’t even want to use the therapy in this limited setting. In a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Biogen is cutting ties with Aduhelm, the Alzheimer’s disease drug that won a landmark but controversial regulatory approval and then became a commercial flop. Development and commercialization of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history ...

Last week, Biogen announced it will cease both the study and sale of Aduhelm, its FDA-approved monoclonal antibody for the treatment of Alzheimer’s disease. Its decision, the company explained, is not ...

The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks. By Rebecca Robbins Biogen said on Tuesday that it would replace its chief ...

Aduhelm (aducanumab-avwa) is a prescription drug that’s used to treat Alzheimer’s disease. The drug comes as a liquid solution for intravenous (IV) infusion by a healthcare professional. It’s usually ...